What is HC Wainwright's Forecast for XOMA FY2025 Earnings?

XOMA Co. (NASDAQ:XOMA - Free Report) - HC Wainwright lifted their FY2025 earnings estimates for XOMA in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn $0.17 per share for the year, up from their previous forecast of $0.15. HC Wainwright has a "Buy" rating and a $117.00 price target on the stock. The consensus estimate for XOMA's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for XOMA's FY2026 earnings at $0.64 EPS.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative return on equity of 24.57% and a negative net margin of 151.34%.

Separately, StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Wednesday, August 14th.

XOMA Stock Up 0.3 %

Shares of XOMA stock traded up $0.10 during trading hours on Monday, hitting $31.07. 16,391 shares of the company were exchanged, compared to its average volume of 21,079. The business has a 50 day moving average of $28.49 and a two-hundred day moving average of $26.74. The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $363.64 million, a PE ratio of -8.87 and a beta of 0.90. XOMA has a 52 week low of $14.33 and a 52 week high of $33.78.

Institutional Investors Weigh In On XOMA

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after buying an additional 1,968 shares in the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of XOMA during the third quarter worth about $516,000. Rhumbline Advisers grew its position in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock valued at $230,000 after buying an additional 1,334 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in XOMA during the 1st quarter worth $212,000. Finally, BNP Paribas Financial Markets raised its position in shares of XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 1,266 shares during the period. Hedge funds and other institutional investors own 95.92% of the company's stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.